It definitely is a massive deterrence for many of the larger more conservative investors. However when the FDA approval arrives and the subsequent "hard numbers" are released to the market, this will be seen as a genuine pharmaceutical company, not merely a "weed stock", and finally we should see a proper valuation. In the meantime, the mismatch between the price and the fundamentals presents a major opportunity for the better researched investors IMO
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.015(9.68%) |
Mkt cap ! $333.3M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 17.0¢ | 15.5¢ | $2.249M | 13.69M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 795955 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 2602872 | 48 |
View Market Depth
| Last trade - 16.10pm 22/07/2025 (20 minute delay) ? |
| BOT (ASX) Chart |